BRAF mutation testing in melanoma: results from a German observational multicenter study

被引:0
|
作者
Arndt Hartmann
Peter Schirmacher
William Sterlacci
Winfried Koch
David B. Liesenfeld
Birgit Schif
Claus Garbe
机构
[1] University of Erlangen-Nüremberg,Institute of Pathology
[2] University Medicine Heidelberg,Institute of Pathology
[3] Klinikum Bayreuth,Institute of Pathology
[4] BDS Koch,Division of Dermato
[5] Roche Pharma AG,Oncology
[6] University-Department of Dermatology,undefined
来源
Virchows Archiv | 2019年 / 474卷
关键词
mutation; Melanoma; Quality control; Mutational analysis; Multiple logistic regression;
D O I
暂无
中图分类号
学科分类号
摘要
Quality control of BRAF mutation testing methods used in routine practice is crucial for optimal treatment selection. In this prospective study, we assessed the impact of patient/sample characteristics on BRAF mutation testing results in patients with melanoma, during clinical practice. Data were collected on routine testing practices and documented mutation status in patients with melanoma stages IIIB, IIIC, or IV across 28 diagnostic pathology centers in Germany. Patient/sample data collected included: patient age, location of primary melanoma and metastases, origin of sample, melanoma subtype, and quality of tissue. Statistical influence of patient/sample characteristics on BRAF mutation rate was assessed using multiple logistic regression analyses and statistical models developed to predict the probability of BRAF mutations for individual patient cohorts. Data/samples from 642 patients with melanoma were analyzed. BRAF mutations were documented in 241/642 patients (37.5%). The primary statistical model to predict BRAF mutation rates included: age (continuous), origin of sample, method of mutation analysis, and quality of tissue. Analyses of post hoc collected data identified major deviations between documented mutation rates included in this study vs. routinely recorded mutation rates for three centers. When samples from these centers were excluded, the influence of testing method was no longer statistically significant. The final model included patient age, origin of sample (including metastasis location), and quality of tissue. Once validated in an independent population, this type of model could allow pathology centers to compare the performance of their testing methods with what would be expected based on patient, tumor, and sample characteristics.
引用
收藏
页码:71 / 78
页数:7
相关论文
共 50 条
  • [41] Prevalence of Reverse Triggering in Early ARDS Results From a Multicenter Observational Study
    Rodriguez, Pablo O.
    Tiribelli, Norberto
    Fredes, Sebastian
    Gogniat, Emiliano
    Plotnikow, Gustavo
    Fernandez Ceballos, Ignacio
    Pratto, Romina
    Raimondi, Alejandro
    Guaymas, Maria
    Ilutovich, Santiago
    San Roman, Eduardo
    Madorno, Matias
    Maskin, Patricio
    Brochard, Laurent
    Setten, Mariano
    CHEST, 2021, 159 (01) : 186 - 195
  • [42] Efficacy and Tolerability of Privigen in Secondary Immunodeficiencies - Results from a Multicenter Observational Study
    Slawik, H. R.
    Plath, M.
    Reiser, M.
    Otremba, B.
    Lotichius, P.
    Pfruender, D.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S296 - S296
  • [43] Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study
    Shah, Shweta
    Raskin, Leon
    Cohan, David
    Hamid, Omid
    Freeman, Morganna L.
    MELANOMA MANAGEMENT, 2019, 6 (04)
  • [44] Monosomy 7 in MDS - Interim results from a German multicenter study
    Schanz, J.
    Braulke, F.
    Shirneshan, K.
    Germing, U.
    Nachtkamp, K.
    Luebbert, M.
    Weiss, R.
    Platzbecker, U.
    Haase, D.
    ONKOLOGIE, 2012, 35 : 29 - 30
  • [45] Conservative Treatment of Hemorrhoids: Results of an Observational Multicenter Study
    Evgeny A. Zagriadskiĭ
    Alexey M. Bogomazov
    Evgeny B. Golovko
    Advances in Therapy, 2018, 35 : 1979 - 1992
  • [46] Conservative Treatment of Hemorrhoids: Results of an Observational Multicenter Study
    Zagriadskii, Evgeny A.
    Bogomazov, Alexey M.
    Golovko, Evgeny B.
    ADVANCES IN THERAPY, 2018, 35 (11) : 1979 - 1992
  • [47] Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study
    Jalid Sehouli
    O. Camara
    M. Schmidt
    S. Mahner
    G. Seipelt
    B. Otremba
    B. Schmalfeldt
    H. Tesch
    C. Lorenz-Schlüter
    G. Oskay-Özcelik
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 585 - 591
  • [48] Real fasting times and incidence of pulmonary aspiration in children: Results of a German prospective multicenter observational study
    Bascou, Nicholas A.
    Marcos, Maria C.
    Quintero, Maria L. Beltran
    Roosen-Marcos, Mercedes C.
    Cladis, Franklyn P.
    Poe, Michele D.
    Escolar, Maria L.
    PEDIATRIC ANESTHESIA, 2019, 29 (10) : 1053 - 1059
  • [49] Pegylated liposomal doxorubicin (CAELYXA®) in patients with advanced ovarian cancer: results of a German multicenter observational study
    Sehouli, Jalid
    Camara, O.
    Schmidt, M.
    Mahner, S.
    Seipelt, G.
    Otremba, B.
    Schmalfeldt, B.
    Tesch, H.
    Lorenz-Schlueter, C.
    Oskay-Oezcelik, G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (03) : 585 - 591
  • [50] Concordance of BRAF V600E mutation status in metastatic melanoma patients by comparison of results from circulating tumor DNA and tissue-based testing
    Schadendorf, D.
    Haselmann, V.
    Sucker, A. Antje
    Jones, F.
    Neumaier, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S685 - S685